Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_assertion type Assertion NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_head.
- NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_assertion description "[Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_provenance.
- NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_assertion evidence source_evidence_literature NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_provenance.
- NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_assertion SIO_000772 16633151 NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_provenance.
- NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_assertion wasDerivedFrom befree-2016 NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_provenance.
- NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_assertion wasGeneratedBy ECO_0000203 NP546385.RAE5fi-QHcvJ0u4u1ahT1B4IDLCg_bDm_iFjl2HEH3ppM130_provenance.